• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

FIGUR8 Launches with $7.5M in Seed Funding to Help Clinicians Make Better Informed Clinical Decisions through Advanced Human Movement Data

Share:

September 3, 2019

Developed by MIT and MGH Scientists, FIGUR8’s Sensor Platform Captures Micrometer Precision Muscle and Joint Movement to Accurately Diagnose Soft-Tissue Injuries

FIGUR8 today announced the launch of the first digital health platform to objectively measure and longitudinally track body movement as a biomarker. In just minutes, clinicians can take clients through a FIGUR8 assessment to establish a movement health baseline, diagnose movement dysfunction, identify injury risk, optimize exercise routines and monitor progress. The company’s highly accurate, cost-effective and portable on-body assessment system was developed in collaboration between Massachusetts General Hospital (MGH) Sports Science Lab and MIT Media Lab researchers.

During any movement, FIGUR8’s patented sensor technology quantifies a combination of micrometer precision signals of muscle activity and joint mobility. From a single movement assessment, over one million unique data points are produced and instantly analyzed by sophisticated algorithms to generate actionable biomechanical insights for clinicians.

FIGUR8’s breakthrough technology reduces the cost of state-of-the-art movement testing equipment by as much as 95 percent and delivers a more effective solution than MRIs and X-rays for screening soft-tissue related symptoms. FIGUR8 is currently working with elite athletes, teams, training facilities and major occupational and physical therapy clinics. These early developmental partnerships allow FIGUR8 to generate data assets that can be used for clinical studies by major medical centers in areas such as Parkinson’s disease and stroke diagnostics and recovery.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“Measuring musculoskeletal performance and recovery has historically been limited to visual and hands-on assessments, providing little to no quantifiable data,” said Habib Haddad of E14 Fund. “This limitation makes accurate, large-scale and cost-effective treatment assessments nearly impossible. We believe FIGUR8 has identified a significant technological breakthrough and look forward to advancing the understanding of human movement through the company’s groundbreaking sensor technologies.”

FIGUR8 developed its diagnostics platform through a seed round led by P5 Health Ventures with participation from E14 Fund, and other individual investors. FIGUR8’s total investment to date is $7.5 million. The company offers healthcare professionals an advanced movement assessment system designed to be used in nearly any environment, without the need for cumbersome and expensive cameras. FIGUR8 combines lightweight, low-profile and highly accurate sensors with proprietary algorithms to map sensor information with the biomechanics of the human body. The company’s award-winning FlexTech Sensors can be manually applied to multiple body locations in a matter of minutes to collect data unobtrusively. The advanced movement data – including muscle activation timing and intensity with joint angles, acceleration and motion in 3D space – is then made instantly available through an all-in-one, easy-to-use web-based platform.

“FIGUR8 is completely unique in its ability to aid clinicians in quantifying mobility health markers captured during any activity,” said FIGUR8 CEO, Dr. Nan-Wei Gong. “These assessments highlight the weaknesses and anomalies of body segments, which could be a symptom of an injury, disease, or simply a target for performance optimization.”

Date: September 03, 2019

Source: Business Wire

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful BidderScilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder
  • Telenor to acquire majority stake in DNA, has sights on total ownershipTelenor to acquire majority stake in DNA, has sights on total ownership
  • Caris Life Sciences Integrates with Flatiron Health for Molecular TestingCaris Life Sciences Integrates with Flatiron Health for Molecular Testing
  • FDA Approves Medtronic’s Insulin Pump System for People with Type 1 DiabetesFDA Approves Medtronic’s Insulin Pump System for People with Type 1 Diabetes
  • Fertility App Premom Shared Users’ Health Data Without Consent, FTC SaysFertility App Premom Shared Users’ Health Data Without Consent, FTC Says
  • Tia Raises $100M to Build Modern Medical Home for WomenTia Raises $100M to Build Modern Medical Home for Women
  • Current Health, Dexcom Partner to Deliver Continuous, Remote Glucose MonitoringCurrent Health, Dexcom Partner to Deliver Continuous, Remote Glucose Monitoring
  • BIO-PHARMACEUTICAL LOGISTICS MARKET 2022, INDUSTRY SIZE, TRENDS, SHARE, GROWTH, ANALYSIS AND FORECAST TO 2028BIO-PHARMACEUTICAL LOGISTICS MARKET 2022, INDUSTRY SIZE, TRENDS, SHARE, GROWTH, ANALYSIS AND FORECAST TO 2028

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications